Phase 4 N=204 Intravenous Oliceridine and Opioid-related Complications
Major Surgery
Primary: Clinically Meaningful Respiratory Compromise Events — 45 Events
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=240 Intermittent Bolus vs Continuous Infusion Via ESP Catheters RCT
Post Operative Pain
Primary: Opioid Consumption POD 1 — 86.6; 90.5 MME
Phase 4 N=347 Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children
Fever After Vaccination · Fever · Seizures Fever
Primary: Number of Participants With Fever Following Vaccination — 14; 10 Participants
Phase 4 N=101 Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation
Dementia · Cognition Disorders · Cerebral Ischemic Events
Primary: Number of Participants With Incident Dementia Determined by a Formal Diagnosis of Dementia by a Neurologist — 0; 0 Participants
Phase 4 N=26 A Clinical Study to Assess the Efficacy and Safety of a Healing Ointment on Diaper Rash
Diaper Rash
Primary: Skin Texture — 1.8; 0.5; 0 Score on a scale
Phase 4 N=62 Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy
Prostate Cancer
Primary: To Compare Urinary Bladder Radioactivity Observed on Piflufolastat (18F) PET and Flotufolastat (18F) PET. — 29.0; 10.9 ratio — p=<0.001
Phase 4 N=922 Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC
Chagas Disease · Heart Failure
Primary: Hierarchical Composite Endpoint Composed of Time to Cardiovascular (CV) Death, Time to First Heart Failure (HF) Hospitalization, and Relative Change in NT-proBNP From…
Phase 4 N=9 Pharmacokinetics of Omadacycline in Cystic Fibrosis
Cystic Fibrosis
Primary: Cmax — 0.733; 0.595 mg/L
Phase 4 N=32 HF Patients With LVADs Being Treated With SGLT2i
Heart Failure With Reduced Ejection Fraction
Primary: Change in Left Ventricular End-diastolic Dimension (LVEDD) — -1.1; -0.9 centimeters (cm) — p=0.38
Phase 4 N=123 A Safety/Tolerability and PK Study With Azstarys® in Children With ADHD
Attention Deficit/Hyperactivity Disorder
Primary: Changes in Sleep Behavior — -6.5 percentage score change
Phase 4 N=14 Effects of Pregnancy-associated Hormones on THC Metabolism in Women
Pregnancy Related · Cannabis Use
Primary: Dronabinol Exposure — 7.0; 5.6; 5.1; 5.0 nM*h — p=>0.05
Phase 4 N=107 Clubfoot Tenotomy Trial
Clubfoot
Primary: FLACC (Face, Legs, Activity, Cry, Consolability) Scale — 9.5; 8.4 score on a scale (0-10)
Phase 4 N=23 GM-CSF for Reversal of immunopAralysis in pediatriC sEpsis-induced MODS Study
Pediatric Sepsis-induced MODS
Primary: Number of Subjects With Restoration of the TNF-alpha Response — 10; 8 Participants
Phase 4 N=24 Daily Doxycycline to Inform Sexually Transmitted Infection Prophylaxis Regimens
Sexually Transmitted Infection
Primary: Doxycycline Concentration in Rectal Tissue — 2.330 µg/g
Phase 4 N=54 Comparison of Visual Field Assessments Between Three Perimeters
Glaucoma
Primary: Total Acquisition Time (Both Eyes) — 4.44; 7.34; 7.71 minutes